Clinical data | |
---|---|
Trade names | Meptid |
AHFS/ Drugs.com | International Drug Names |
Dependence liability | Low |
Routes of administration | Oral, IM, IV |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours |
Elimination half-life | Half-life (1.4–4 hours) |
Excretion | The drug is rapidly metabolized to the glucuronide, and mostly excreted in the urine |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.053.718 |
Chemical and physical data | |
Formula | C15H23NO |
Molar mass | 233.355 g·mol−1 |
3D model ( JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s. [1] Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics ( childbirth).
Meptazinol is a 3-phenylazepane derivative, whereas the other phenazepanes like ethoheptazine and proheptazine are 4-phenylazepanes.
A partial μ-opioid receptor agonist, its mixed agonist/ antagonist activity affords it a lower risk of dependence and abuse than full μ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine. [2]
Clinical data | |
---|---|
Trade names | Meptid |
AHFS/ Drugs.com | International Drug Names |
Dependence liability | Low |
Routes of administration | Oral, IM, IV |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours |
Elimination half-life | Half-life (1.4–4 hours) |
Excretion | The drug is rapidly metabolized to the glucuronide, and mostly excreted in the urine |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.053.718 |
Chemical and physical data | |
Formula | C15H23NO |
Molar mass | 233.355 g·mol−1 |
3D model ( JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s. [1] Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics ( childbirth).
Meptazinol is a 3-phenylazepane derivative, whereas the other phenazepanes like ethoheptazine and proheptazine are 4-phenylazepanes.
A partial μ-opioid receptor agonist, its mixed agonist/ antagonist activity affords it a lower risk of dependence and abuse than full μ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine. [2]